Tenax Therapeutics Stock Performance
| TENX Stock | USD 11.64 0.11 0.94% |
On a scale of 0 to 100, Tenax Therapeutics holds a performance score of 8. The entity has a beta of 0.68, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tenax Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tenax Therapeutics is expected to be smaller as well. Please check Tenax Therapeutics' jensen alpha, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to make a quick decision on whether Tenax Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tenax Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Tenax Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.09) | Five Day Return (5.62) | Year To Date Return 6.33 | Ten Year Return (99.98) | All Time Return (100.00) |
Last Split Factor 1:80 | Dividend Date 2018-02-26 | Last Split Date 2024-01-03 |
1 | Acquisition by Rich Stuart of 1000 shares of Tenax Therapeutics at 9.0059 subject to Rule 16b-3 | 12/02/2025 |
2 | Acquisition by Rich Stuart of 1500 shares of Tenax Therapeutics at 9.0786 subject to Rule 16b-3 | 12/03/2025 |
3 | Acquisition by Rich Stuart of 2500 shares of Tenax Therapeutics at 10.1002 subject to Rule 16b-3 | 12/08/2025 |
4 | Acquisition by Rich Stuart of 2500 shares of Tenax Therapeutics at 10.2168 subject to Rule 16b-3 | 12/09/2025 |
5 | TenX Protocols, a DeFi Technologies Advisory Client and Venture Investment, Debuts on TSX Venture Exchange as TNX Following Successful 30 Million Financing | 12/10/2025 |
6 | JANUS HENDERSON GROUP PLC Acquires Additional Shares in Tenax Therapeutics Inc - GuruFocus | 12/12/2025 |
7 | Guggenheim Doubles Tenax PT, Names Stock Top Pick | 01/08/2026 |
8 | Tenax Therapeutics Share Price Passes Above Two Hundred Day Moving Average - Heres What Happened - MarketBeat | 01/12/2026 |
9 | Acquisition by Doogan Declan of 30000 shares of Tenax Therapeutics at 13.3 subject to Rule 16b-3 | 01/13/2026 |
10 | Insider Trading | 01/28/2026 |
11 | Acquisition by Thomas McGauley of 50000 shares of Tenax Therapeutics at 12.51 subject to Rule 16b-3 | 01/30/2026 |
12 | Acquisition by Davidson Michael H. of 47500 shares of Tenax Therapeutics at 0.01 subject to Rule 16b-3 | 02/06/2026 |
13 | Tenax Therapeutics Stock Passes Above 200 Day Moving Average - Whats Next - MarketBeat | 02/13/2026 |
14 | and the Role of Price-Sensitive Allocations - Stock Traders Daily | 02/19/2026 |
Tenax Therapeutics Relative Risk vs. Return Landscape
If you would invest 907.00 in Tenax Therapeutics on November 29, 2025 and sell it today you would earn a total of 268.00 from holding Tenax Therapeutics or generate 29.55% return on investment over 90 days. Tenax Therapeutics is currently generating 0.5689% in daily expected returns and assumes 5.3453% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Tenax, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tenax Therapeutics Target Price Odds to finish over Current Price
The tendency of Tenax Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.64 | 90 days | 11.64 | about 61.01 |
Based on a normal probability distribution, the odds of Tenax Therapeutics to move above the current price in 90 days from now is about 61.01 (This Tenax Therapeutics probability density function shows the probability of Tenax Stock to fall within a particular range of prices over 90 days) .
Tenax Therapeutics Price Density |
| Price |
Predictive Modules for Tenax Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tenax Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tenax Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tenax Therapeutics is not an exception. The market had few large corrections towards the Tenax Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tenax Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tenax Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.69 | |
β | Beta against Dow Jones | 0.68 | |
σ | Overall volatility | 2.11 | |
Ir | Information ratio | 0.12 |
Tenax Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tenax Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tenax Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tenax Therapeutics is way too risky over 90 days horizon | |
| Tenax Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (17.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenax Therapeutics currently holds about 7.23 M in cash with (14.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Tenax Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: and the Role of Price-Sensitive Allocations - Stock Traders Daily |
Tenax Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tenax Stock often depends not only on the future outlook of the current and potential Tenax Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tenax Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.3 M | |
| Cash And Short Term Investments | 94.9 M |
Tenax Therapeutics Fundamentals Growth
Tenax Stock prices reflect investors' perceptions of the future prospects and financial health of Tenax Therapeutics, and Tenax Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tenax Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 68.19 M | ||||
| Shares Outstanding | 6.24 M | ||||
| Price To Earning | (0.35) X | ||||
| Price To Book | 0.80 X | ||||
| EBITDA | (17.58 M) | ||||
| Net Income | (17.6 M) | ||||
| Cash And Equivalents | 7.23 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 4.69 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.60 X | ||||
| Book Value Per Share | 2.39 X | ||||
| Cash Flow From Operations | (14.81 M) | ||||
| Earnings Per Share | (0.74) X | ||||
| Market Capitalization | 77.3 M | ||||
| Total Asset | 96.69 M | ||||
| Retained Earnings | (314.86 M) | ||||
| Working Capital | 91.99 M | ||||
| Current Asset | 21.86 M | ||||
| Current Liabilities | 3.56 M | ||||
About Tenax Therapeutics Performance
Evaluating Tenax Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tenax Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tenax Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 315.09 | 299.34 | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.22) | (0.21) |
Things to note about Tenax Therapeutics performance evaluation
Checking the ongoing alerts about Tenax Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tenax Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tenax Therapeutics is way too risky over 90 days horizon | |
| Tenax Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (17.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenax Therapeutics currently holds about 7.23 M in cash with (14.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Tenax Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: and the Role of Price-Sensitive Allocations - Stock Traders Daily |
- Analyzing Tenax Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tenax Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tenax Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tenax Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tenax Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tenax Therapeutics' stock. These opinions can provide insight into Tenax Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.